<DOC>
	<DOC>NCT00787150</DOC>
	<brief_summary>To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.</brief_summary>
	<brief_title>A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age â‰¥ 20 years outpatient (regardless of sex) Patients diagnosed as nonvalvular atrial fibrillation (NVAF) One or more following risks of stroke. Recent cerebral infarction (includes TIA) within 4 weeks of week 0. Subjects who have or are suspected to have a serious/hereditary bleeding tendency, such as disseminated intravascular coagulation syndrome (DIC), congenital platelet dysfunction and von Willebrand disease (those suspected from the family history are included). Subjects who have or are suspected to have a serious/hereditary thrombogenic tendency (those suspected from the family history are included) or those who require continuation of the Warfarin therapy.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>